| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
Blood
|
2011
|
5.06
|
|
2
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Clin Cancer Res
|
2012
|
3.48
|
|
3
|
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
|
Blood
|
2009
|
2.66
|
|
4
|
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
|
Blood
|
2009
|
2.50
|
|
5
|
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
|
Blood
|
2003
|
2.06
|
|
6
|
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
|
Blood
|
2005
|
2.06
|
|
7
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
Blood
|
2004
|
2.03
|
|
8
|
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
|
Blood
|
2003
|
1.94
|
|
9
|
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
|
Blood
|
2008
|
1.80
|
|
10
|
hTERT associates with human telomeres and enhances genomic stability and DNA repair.
|
Oncogene
|
2003
|
1.78
|
|
11
|
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
|
J Clin Oncol
|
2003
|
1.67
|
|
12
|
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
|
Blood
|
2009
|
1.62
|
|
13
|
Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome.
|
Cell
|
2006
|
1.61
|
|
14
|
Relationship between hip and knee strength and knee valgus during a single leg squat.
|
J Appl Biomech
|
2006
|
1.58
|
|
15
|
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells.
|
Leuk Lymphoma
|
2012
|
1.48
|
|
16
|
miRNAs and their potential for use against cancer and other diseases.
|
Future Oncol
|
2007
|
1.47
|
|
17
|
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
|
Blood
|
2009
|
1.42
|
|
18
|
Biochemical modulation of cytarabine triphosphate by clofarabine.
|
Cancer Chemother Pharmacol
|
2004
|
1.40
|
|
19
|
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.
|
Leuk Lymphoma
|
2012
|
1.40
|
|
20
|
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
1.36
|
|
21
|
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
|
J Pharmacol Exp Ther
|
2007
|
1.34
|
|
22
|
Clofarabine: past, present, and future.
|
Leuk Lymphoma
|
2007
|
1.31
|
|
23
|
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
|
Blood
|
2011
|
1.27
|
|
24
|
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
|
Blood
|
2005
|
1.23
|
|
25
|
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
|
Blood
|
2007
|
1.19
|
|
26
|
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
|
Cancer Res
|
2006
|
1.18
|
|
27
|
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
|
Blood
|
2006
|
1.15
|
|
28
|
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
|
Leuk Res
|
2003
|
1.13
|
|
29
|
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
|
J Clin Oncol
|
2002
|
1.12
|
|
30
|
Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs.
|
J Am Chem Soc
|
2011
|
1.11
|
|
31
|
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
|
Expert Opin Investig Drugs
|
2006
|
1.09
|
|
32
|
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.
|
Blood
|
2003
|
1.09
|
|
33
|
RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells.
|
Cancer Res
|
2003
|
1.09
|
|
34
|
MET receptor tyrosine kinase as a therapeutic anticancer target.
|
Cancer Lett
|
2008
|
1.08
|
|
35
|
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase.
|
Cancer Res
|
2007
|
1.07
|
|
36
|
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.
|
Blood
|
2005
|
1.06
|
|
37
|
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
Cancer
|
2011
|
1.06
|
|
38
|
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.
|
Bioinformatics
|
2009
|
1.05
|
|
39
|
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma.
|
Mol Cancer Ther
|
2005
|
1.04
|
|
40
|
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
J Clin Oncol
|
2010
|
1.04
|
|
41
|
Quadriceps femoris electromyogram during concentric, isometric and eccentric phases of fatiguing dynamic knee extensions.
|
J Biomech
|
2006
|
1.04
|
|
42
|
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
|
Cancer
|
2005
|
1.03
|
|
43
|
Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine.
|
J Biol Chem
|
2009
|
1.03
|
|
44
|
RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells.
|
Br J Haematol
|
2008
|
1.02
|
|
45
|
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
|
Ther Deliv
|
2012
|
1.02
|
|
46
|
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
|
Blood
|
2010
|
1.02
|
|
47
|
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
|
J Pharmacol Exp Ther
|
2011
|
1.00
|
|
48
|
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis.
|
Br J Haematol
|
2009
|
0.99
|
|
49
|
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
|
Blood
|
2010
|
0.98
|
|
50
|
Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
|
Blood
|
2012
|
0.96
|
|
51
|
Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.
|
Clin Cancer Res
|
2009
|
0.95
|
|
52
|
8-amino-adenosine is a potential therapeutic agent for multiple myeloma.
|
Mol Cancer Ther
|
2004
|
0.94
|
|
53
|
A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.
|
Breast Cancer Res Treat
|
2009
|
0.94
|
|
54
|
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
|
Pharmacogenomics
|
2011
|
0.93
|
|
55
|
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
|
Br J Haematol
|
2008
|
0.92
|
|
56
|
Bcl-2 antagonists: a proof of concept for CLL therapy.
|
Invest New Drugs
|
2013
|
0.92
|
|
57
|
Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues.
|
Biochem Pharmacol
|
2009
|
0.92
|
|
58
|
8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.
|
Blood
|
2010
|
0.92
|
|
59
|
Inhibition of ATP synthase by chlorinated adenosine analogue.
|
Biochem Pharmacol
|
2009
|
0.91
|
|
60
|
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
|
Cancer Res
|
2010
|
0.91
|
|
61
|
Targeting MET transcription as a therapeutic strategy in multiple myeloma.
|
Cancer Chemother Pharmacol
|
2008
|
0.91
|
|
62
|
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
|
Neoplasia
|
2010
|
0.90
|
|
63
|
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.
|
Biochem Pharmacol
|
2010
|
0.90
|
|
64
|
8-Amino-adenosine inhibits multiple mechanisms of transcription.
|
Mol Cancer Ther
|
2010
|
0.90
|
|
65
|
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
|
Blood
|
2006
|
0.88
|
|
66
|
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine.
|
Clin Cancer Res
|
2005
|
0.88
|
|
67
|
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
|
J Clin Pharmacol
|
2004
|
0.88
|
|
68
|
Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells.
|
Mol Cancer Ther
|
2006
|
0.88
|
|
69
|
Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.87
|
|
70
|
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
|
Cancer Res
|
2002
|
0.86
|
|
71
|
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
|
Cancer
|
2005
|
0.86
|
|
72
|
Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.
|
Cancer Res
|
2009
|
0.85
|
|
73
|
Targeting the apoptosis pathway in hematologic malignancies.
|
Leuk Lymphoma
|
2014
|
0.85
|
|
74
|
Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2013
|
0.85
|
|
75
|
Defective molecular timer in the absence of nucleotides leads to inefficient caspase activation.
|
PLoS One
|
2011
|
0.84
|
|
76
|
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
|
Mol Cancer Ther
|
2002
|
0.84
|
|
77
|
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.
|
Mol Pharmacol
|
2002
|
0.84
|
|
78
|
Questions about gemcitabine dose rate: answered or unanswered?
|
J Clin Oncol
|
2007
|
0.82
|
|
79
|
The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions.
|
Blood
|
2009
|
0.82
|
|
80
|
Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes.
|
J Med Chem
|
2014
|
0.82
|
|
81
|
Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial.
|
Trials
|
2014
|
0.82
|
|
82
|
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
|
Pharmacogenomics
|
2013
|
0.81
|
|
83
|
Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.81
|
|
84
|
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.
|
Leuk Res
|
2008
|
0.80
|
|
85
|
Forodesine: review of preclinical and clinical data.
|
Future Oncol
|
2010
|
0.80
|
|
86
|
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.
|
PLoS One
|
2012
|
0.80
|
|
87
|
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
|
Curr Opin Hematol
|
2008
|
0.79
|
|
88
|
DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.
|
Leuk Lymphoma
|
2013
|
0.79
|
|
89
|
ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
|
J Pharmacol Exp Ther
|
2011
|
0.78
|
|
90
|
Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels.
|
J Biol Chem
|
2010
|
0.78
|
|
91
|
Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).
|
Br J Haematol
|
2008
|
0.78
|
|
92
|
In vitro assessment of nucleoside analogs in multiple myeloma.
|
Cancer Chemother Pharmacol
|
2004
|
0.78
|
|
93
|
Nelarabine.
|
Nat Rev Drug Discov
|
2006
|
0.77
|
|
94
|
Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport.
|
Leuk Lymphoma
|
2007
|
0.77
|
|
95
|
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.77
|
|
96
|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.77
|
|
97
|
Myeloma antioxidant status: the good, the bad and the reactive.
|
Leuk Lymphoma
|
2009
|
0.76
|
|
98
|
New nucleoside analogues in clinical development.
|
Cancer Chemother Biol Response Modif
|
2002
|
0.76
|
|
99
|
The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G.
|
Biochem Pharmacol
|
2003
|
0.76
|
|
100
|
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.
|
Expert Opin Investig Drugs
|
2012
|
0.75
|
|
101
|
Yet another nucleoside analog for pancreatic cancer.
|
Gastroenterology
|
2010
|
0.75
|
|
102
|
The micros in harmony: microRNA and microenvironment.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
103
|
Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
104
|
Dialing resistance up a Notch.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
105
|
Modifying the immune system to treat chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
106
|
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
|
Nucleosides Nucleotides Nucleic Acids
|
2004
|
0.75
|
|
107
|
Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells.
|
Mol Cancer Ther
|
2002
|
0.75
|
|
108
|
Concurrent isolation of ribosomal, messenger, and low molecular weight RNA.
|
Biotechniques
|
2002
|
0.75
|